Provention faces delay in FDA review of diabetes prevention antibodyThe FDA says it has uncovered “deficiencies” in the marketing application for Provention Bio’s much-anticipated drug teplizumab for Share XProvention faces delay in FDA review of diabetes prevention antibodyhttps://pharmaphorum.com/news/provention-faces-delay-in-fda-review-of-diabetes-prevention-antibody/
FDA fast tracks type 1 diabetes cell therapy from VertexVertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and Share XFDA fast tracks type 1 diabetes cell therapy from Vertexhttps://pharmaphorum.com/news/vertex-claims-fda-fast-track-status-for-diabetes-cell-therapy/
FDA approves Tandem’s connected insulin controllerTandem Diabetes Care has claimed approval in the US for a new software system that can be used Share XFDA approves Tandem’s connected insulin controllerhttps://pharmaphorum.com/news/fda-approves-tandems-connected-insulin-controller/
Sanofi builds case for Toujeo in younger type 1 diabeticsSanofi’s Toujeo – a follow-up to its long-acting insulin drug Lantus – has underperformed commercially since launch but Share XSanofi builds case for Toujeo in younger type 1 diabeticshttps://pharmaphorum.com/news/sanofi-builds-case-for-toujeo-in-younger-type-1-diabetics/
Astellas cuts $795m deal with Pandion for type 1 diabetes drugsAstellas Pharma is boosting its early-stage pipeline with a $45 million upfront deal to license bispecific antibodies from Share XAstellas cuts $795m deal with Pandion for type 1 diabetes drugshttps://pharmaphorum.com/news/astellas-biotech-deal-pandion-diabetes/
Giving patients a sense of belongingClinical research professional and patient advocate Kristina Wolfe tells us how pharma can collaborate better with patients and Share XGiving patients a sense of belonginghttps://pharmaphorum.com/views-analysis-patients/giving-patients-a-sense-of-belonging/
Vertex looks beyond cystic fibrosis with $950m Semma buyVertex Pharma is all-but synonymous with cystic fibrosis (CF) treatment but wants to diversify into new areas, including Share XVertex looks beyond cystic fibrosis with $950m Semma buyhttps://pharmaphorum.com/news/vertex-looks-beyond-cystic-fibrosis-with-950m-semma-buy/
Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerGlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid Share XRelief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerhttps://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/
FDA unconvinced by Sanofi’s Zynquista in type 1 diabetesSanofi’s hopes of getting its dual SGLT inhibitor sotagliflozin approved alongside insulin for type 1 diabetes in the Share XFDA unconvinced by Sanofi’s Zynquista in type 1 diabeteshttps://pharmaphorum.com/news/fda-unconvinced-by-sanofis-zynquista-in-type-1-diabetes/
